Orexo has submitted its Vorvida digital therapy for the treatment of heavy drinking for approval by the FDA, setting up a possible launch in the second half of this year. The Swedish drugmaker ...

anaphylaxis) with powder-based epinephrine. OX640 is based on Orexo's proprietary drug delivery platform, AmorphOX ®, and has demonstrated positive data in a phase 1 clinical study in healthy ...

anaphylaxis) with powder-based epinephrine. OX640 is based on Orexo´s proprietary drug delivery platform, AmorphOX ®, and has demonstrated positive data in a phase 1 clinical study in healthy ...

You can also follow Orexo on X, LinkedIn, and YouTube. The information was submitted for publication at 3 pm CET on October 25, 2024. Aulisa® Medical USA, Inc., a leader in FDA-cleared ...

Orexo AB (ORXOY) faced setbacks with the FDA approval process for OX 124, requiring additional tests and manufacturing, leading to delays. The company experienced a decline in net revenues by 11.4 ...

anaphylaxis) with powder-based epinephrine. OX640 is based on Orexo´s proprietary drug delivery platform, AmorphOX®, and has demonstrated positive data in a phase 1 clinical study in healthy ...

According to the release, the United States Food and Drug Administration (FDA) has accepted Telix's New Drug Application (NDA) for Pixclara, which is an agent for the imaging of glioma.

› Total net revenues of SEK 136.5 m (156.1) › EBITDA of SEK -0.7 m (-9.5) › Net earnings of SEK -41.9 m (-33.3) › US Commercial segment net revenues of SEK 131.0 m (140.4), in local ...

The third quarter has been challenging, starting with the delay of OX124's approval and, from a financial perspective, we had a marginally negative EBITDA. This negative EBITDA result was primarily ...

This information is information that Orexo AB (publ.) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the ...